David Mott

David Mott has served on Ardelyx’s board of directors since March 2009 and has been the chairperson of the board of directors since March 2014. David is currently a private investor through Mott Family Capital.

From September 2008 to February 2020, David served as a general partner of New Enterprise Associates (NEA), an investment firm focused on venture capital and growth equity investments, where he led the healthcare investing practice.

Prior to joining NEA, David worked at MedImmune, a biotechnology company and subsidiary of AstraZeneca, and served in numerous roles during his tenure, including president and chief executive officer, chief financial officer, and president and chief operating officer. During that time, David also served as executive vice president of AstraZeneca, following AstraZeneca Plc’s acquisition of Medimmune in June 2007.

Earlier in his career, he was a vice president in the healthcare investment banking group at Smith Barney, Harris Upham & Co. Inc.

David serves as the chairperson of the board of directors for Adaptimmune, and Mersana Therapeutics, and serves on the board of directors of Novavax. Dave is also Chair of the Board for Adaptimmune and Mersana and is a member of the board for Novovax.

He earned a B.A. in Economics and Government from Dartmouth College.